Table of Content

1 Study Coverage
1.1 Neurodegenerative Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Neurodegenerative Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 NMDA
1.2.3 SSRIs
1.2.4 Dopamine Inhibitors
1.3 Market by Application
1.3.1 Global Neurodegenerative Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Parkinson’s Disease
1.3.3 Huntington Disease
1.3.4 Amyotrophic Lateral Sclerosis
1.3.5 Alzheimer’s Disease
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Neurodegenerative Drugs Sales Estimates and Forecasts 2018-2029
2.2 Global Neurodegenerative Drugs Revenue by Region
2.2.1 Global Neurodegenerative Drugs Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Neurodegenerative Drugs Revenue by Region (2018-2024)
2.2.3 Global Neurodegenerative Drugs Revenue by Region (2024-2029)
2.2.4 Global Neurodegenerative Drugs Revenue Market Share by Region (2018-2029)
2.3 Global Neurodegenerative Drugs Sales Estimates and Forecasts 2018-2029
2.4 Global Neurodegenerative Drugs Sales by Region
2.4.1 Global Neurodegenerative Drugs Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Neurodegenerative Drugs Sales by Region (2018-2024)
2.4.3 Global Neurodegenerative Drugs Sales by Region (2024-2029)
2.4.4 Global Neurodegenerative Drugs Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Neurodegenerative Drugs Sales by Manufacturers
3.1.1 Global Neurodegenerative Drugs Sales by Manufacturers (2018-2024)
3.1.2 Global Neurodegenerative Drugs Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Neurodegenerative Drugs in 2022
3.2 Global Neurodegenerative Drugs Revenue by Manufacturers
3.2.1 Global Neurodegenerative Drugs Revenue by Manufacturers (2018-2024)
3.2.2 Global Neurodegenerative Drugs Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Neurodegenerative Drugs Revenue in 2022
3.3 Global Key Players of Neurodegenerative Drugs, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Neurodegenerative Drugs Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Neurodegenerative Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Neurodegenerative Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Neurodegenerative Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Neurodegenerative Drugs Sales by Type
4.1.1 Global Neurodegenerative Drugs Historical Sales by Type (2018-2024)
4.1.2 Global Neurodegenerative Drugs Forecasted Sales by Type (2024-2029)
4.1.3 Global Neurodegenerative Drugs Sales Market Share by Type (2018-2029)
4.2 Global Neurodegenerative Drugs Revenue by Type
4.2.1 Global Neurodegenerative Drugs Historical Revenue by Type (2018-2024)
4.2.2 Global Neurodegenerative Drugs Forecasted Revenue by Type (2024-2029)
4.2.3 Global Neurodegenerative Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Neurodegenerative Drugs Price by Type
4.3.1 Global Neurodegenerative Drugs Price by Type (2018-2024)
4.3.2 Global Neurodegenerative Drugs Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Neurodegenerative Drugs Sales by Application
5.1.1 Global Neurodegenerative Drugs Historical Sales by Application (2018-2024)
5.1.2 Global Neurodegenerative Drugs Forecasted Sales by Application (2024-2029)
5.1.3 Global Neurodegenerative Drugs Sales Market Share by Application (2018-2029)
5.2 Global Neurodegenerative Drugs Revenue by Application
5.2.1 Global Neurodegenerative Drugs Historical Revenue by Application (2018-2024)
5.2.2 Global Neurodegenerative Drugs Forecasted Revenue by Application (2024-2029)
5.2.3 Global Neurodegenerative Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Neurodegenerative Drugs Price by Application
5.3.1 Global Neurodegenerative Drugs Price by Application (2018-2024)
5.3.2 Global Neurodegenerative Drugs Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Neurodegenerative Drugs Market Size by Type
6.1.1 US & Canada Neurodegenerative Drugs Sales by Type (2018-2029)
6.1.2 US & Canada Neurodegenerative Drugs Revenue by Type (2018-2029)
6.2 US & Canada Neurodegenerative Drugs Market Size by Application
6.2.1 US & Canada Neurodegenerative Drugs Sales by Application (2018-2029)
6.2.2 US & Canada Neurodegenerative Drugs Revenue by Application (2018-2029)
6.3 US & Canada Neurodegenerative Drugs Market Size by Country
6.3.1 US & Canada Neurodegenerative Drugs Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Neurodegenerative Drugs Sales by Country (2018-2029)
6.3.3 US & Canada Neurodegenerative Drugs Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Neurodegenerative Drugs Market Size by Type
7.1.1 Europe Neurodegenerative Drugs Sales by Type (2018-2029)
7.1.2 Europe Neurodegenerative Drugs Revenue by Type (2018-2029)
7.2 Europe Neurodegenerative Drugs Market Size by Application
7.2.1 Europe Neurodegenerative Drugs Sales by Application (2018-2029)
7.2.2 Europe Neurodegenerative Drugs Revenue by Application (2018-2029)
7.3 Europe Neurodegenerative Drugs Market Size by Country
7.3.1 Europe Neurodegenerative Drugs Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Neurodegenerative Drugs Sales by Country (2018-2029)
7.3.3 Europe Neurodegenerative Drugs Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Neurodegenerative Drugs Market Size
8.1.1 China Neurodegenerative Drugs Sales (2018-2029)
8.1.2 China Neurodegenerative Drugs Revenue (2018-2029)
8.2 China Neurodegenerative Drugs Market Size by Application
8.2.1 China Neurodegenerative Drugs Sales by Application (2018-2029)
8.2.2 China Neurodegenerative Drugs Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Neurodegenerative Drugs Market Size by Type
9.1.1 Asia Neurodegenerative Drugs Sales by Type (2018-2029)
9.1.2 Asia Neurodegenerative Drugs Revenue by Type (2018-2029)
9.2 Asia Neurodegenerative Drugs Market Size by Application
9.2.1 Asia Neurodegenerative Drugs Sales by Application (2018-2029)
9.2.2 Asia Neurodegenerative Drugs Revenue by Application (2018-2029)
9.3 Asia Neurodegenerative Drugs Sales by Region
9.3.1 Asia Neurodegenerative Drugs Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Neurodegenerative Drugs Revenue by Region (2018-2029)
9.3.3 Asia Neurodegenerative Drugs Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Neurodegenerative Drugs Market Size by Type
10.1.1 Middle East, Africa and Latin America Neurodegenerative Drugs Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Neurodegenerative Drugs Market Size by Application
10.2.1 Middle East, Africa and Latin America Neurodegenerative Drugs Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Neurodegenerative Drugs Sales by Country
10.3.1 Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Neurodegenerative Drugs Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis Overview
11.1.3 Novartis Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Novartis Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Novartis Recent Developments
11.2 Pfizer
11.2.1 Pfizer Company Information
11.2.2 Pfizer Overview
11.2.3 Pfizer Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Pfizer Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Pfizer Recent Developments
11.3 Merck Serono
11.3.1 Merck Serono Company Information
11.3.2 Merck Serono Overview
11.3.3 Merck Serono Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Merck Serono Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Merck Serono Recent Developments
11.4 Biogen Idec
11.4.1 Biogen Idec Company Information
11.4.2 Biogen Idec Overview
11.4.3 Biogen Idec Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Biogen Idec Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Biogen Idec Recent Developments
11.5 TEVA
11.5.1 TEVA Company Information
11.5.2 TEVA Overview
11.5.3 TEVA Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 TEVA Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 TEVA Recent Developments
11.6 UCB
11.6.1 UCB Company Information
11.6.2 UCB Overview
11.6.3 UCB Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 UCB Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 UCB Recent Developments
11.7 Boehringer Ingelheim
11.7.1 Boehringer Ingelheim Company Information
11.7.2 Boehringer Ingelheim Overview
11.7.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Boehringer Ingelheim Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Boehringer Ingelheim Recent Developments
11.8 Sanofi
11.8.1 Sanofi Company Information
11.8.2 Sanofi Overview
11.8.3 Sanofi Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Sanofi Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Sanofi Recent Developments
11.9 GlaxoSmithKline
11.9.1 GlaxoSmithKline Company Information
11.9.2 GlaxoSmithKline Overview
11.9.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 GlaxoSmithKline Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 GlaxoSmithKline Recent Developments
11.10 Livzon Pharmaceutical
11.10.1 Livzon Pharmaceutical Company Information
11.10.2 Livzon Pharmaceutical Overview
11.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Livzon Pharmaceutical Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Livzon Pharmaceutical Recent Developments
11.11 Haisco Pharmaceutical
11.11.1 Haisco Pharmaceutical Company Information
11.11.2 Haisco Pharmaceutical Overview
11.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Haisco Pharmaceutical Recent Developments
11.12 Jingxin Pharmaceutical
11.12.1 Jingxin Pharmaceutical Company Information
11.12.2 Jingxin Pharmaceutical Overview
11.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 Jingxin Pharmaceutical Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Jingxin Pharmaceutical Recent Developments
11.13 Dongcheng Biochemicals
11.13.1 Dongcheng Biochemicals Company Information
11.13.2 Dongcheng Biochemicals Overview
11.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.13.4 Dongcheng Biochemicals Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Dongcheng Biochemicals Recent Developments
11.14 Hisun Pharmaceutical
11.14.1 Hisun Pharmaceutical Company Information
11.14.2 Hisun Pharmaceutical Overview
11.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.14.4 Hisun Pharmaceutical Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Hisun Pharmaceutical Recent Developments
11.15 Luye Pharma
11.15.1 Luye Pharma Company Information
11.15.2 Luye Pharma Overview
11.15.3 Luye Pharma Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.15.4 Luye Pharma Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Luye Pharma Recent Developments
11.16 Ark Pharmaceutical
11.16.1 Ark Pharmaceutical Company Information
11.16.2 Ark Pharmaceutical Overview
11.16.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.16.4 Ark Pharmaceutical Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Ark Pharmaceutical Recent Developments
11.17 Kanghong Pharmaceutical
11.17.1 Kanghong Pharmaceutical Company Information
11.17.2 Kanghong Pharmaceutical Overview
11.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.17.4 Kanghong Pharmaceutical Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Kanghong Pharmaceutical Recent Developments
11.18 Huahai Pharmaceutical
11.18.1 Huahai Pharmaceutical Company Information
11.18.2 Huahai Pharmaceutical Overview
11.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.18.4 Huahai Pharmaceutical Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Huahai Pharmaceutical Recent Developments
11.19 BORA PHARMACEUTICALS
11.19.1 BORA PHARMACEUTICALS Company Information
11.19.2 BORA PHARMACEUTICALS Overview
11.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.19.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 BORA PHARMACEUTICALS Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Neurodegenerative Drugs Industry Chain Analysis
12.2 Neurodegenerative Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Neurodegenerative Drugs Production Mode & Process
12.4 Neurodegenerative Drugs Sales and Marketing
12.4.1 Neurodegenerative Drugs Sales Channels
12.4.2 Neurodegenerative Drugs Distributors
12.5 Neurodegenerative Drugs Customers
13 Market Dynamics
13.1 Neurodegenerative Drugs Industry Trends
13.2 Neurodegenerative Drugs Market Drivers
13.3 Neurodegenerative Drugs Market Challenges
13.4 Neurodegenerative Drugs Market Restraints
14 Key Findings in The Global Neurodegenerative Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Neurodegenerative Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of NMDA
Table 3. Major Manufacturers of SSRIs
Table 4. Major Manufacturers of Dopamine Inhibitors
Table 5. Global Neurodegenerative Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Neurodegenerative Drugs Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Neurodegenerative Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Neurodegenerative Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 9. Global Neurodegenerative Drugs Revenue Market Share by Region (2018-2024)
Table 10. Global Neurodegenerative Drugs Revenue Market Share by Region (2024-2029)
Table 11. Global Neurodegenerative Drugs Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 12. Global Neurodegenerative Drugs Sales by Region (2018-2024) & (MT)
Table 13. Global Neurodegenerative Drugs Sales by Region (2024-2029) & (MT)
Table 14. Global Neurodegenerative Drugs Sales Market Share by Region (2018-2024)
Table 15. Global Neurodegenerative Drugs Sales Market Share by Region (2024-2029)
Table 16. Global Neurodegenerative Drugs Sales by Manufacturers (2018-2024) & (MT)
Table 17. Global Neurodegenerative Drugs Sales Share by Manufacturers (2018-2024)
Table 18. Global Neurodegenerative Drugs Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Neurodegenerative Drugs Revenue Share by Manufacturers (2018-2024)
Table 20. Global Key Players of Neurodegenerative Drugs, Industry Ranking, 2021 VS 2022 VS 2024
Table 21. Neurodegenerative Drugs Price by Manufacturers 2018-2024 (US$/MT)
Table 22. Global Neurodegenerative Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Neurodegenerative Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Drugs as of 2022)
Table 24. Global Key Manufacturers of Neurodegenerative Drugs, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Neurodegenerative Drugs, Product Offered and Application
Table 26. Global Key Manufacturers of Neurodegenerative Drugs, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Neurodegenerative Drugs Sales by Type (2018-2024) & (MT)
Table 29. Global Neurodegenerative Drugs Sales by Type (2024-2029) & (MT)
Table 30. Global Neurodegenerative Drugs Sales Share by Type (2018-2024)
Table 31. Global Neurodegenerative Drugs Sales Share by Type (2024-2029)
Table 32. Global Neurodegenerative Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Neurodegenerative Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 34. Global Neurodegenerative Drugs Revenue Share by Type (2018-2024)
Table 35. Global Neurodegenerative Drugs Revenue Share by Type (2024-2029)
Table 36. Neurodegenerative Drugs Price by Type (2018-2024) & (US$/MT)
Table 37. Global Neurodegenerative Drugs Price Forecast by Type (2024-2029) & (US$/MT)
Table 38. Global Neurodegenerative Drugs Sales by Application (2018-2024) & (MT)
Table 39. Global Neurodegenerative Drugs Sales by Application (2024-2029) & (MT)
Table 40. Global Neurodegenerative Drugs Sales Share by Application (2018-2024)
Table 41. Global Neurodegenerative Drugs Sales Share by Application (2024-2029)
Table 42. Global Neurodegenerative Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Neurodegenerative Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 44. Global Neurodegenerative Drugs Revenue Share by Application (2018-2024)
Table 45. Global Neurodegenerative Drugs Revenue Share by Application (2024-2029)
Table 46. Neurodegenerative Drugs Price by Application (2018-2024) & (US$/MT)
Table 47. Global Neurodegenerative Drugs Price Forecast by Application (2024-2029) & (US$/MT)
Table 48. US & Canada Neurodegenerative Drugs Sales by Type (2018-2024) & (MT)
Table 49. US & Canada Neurodegenerative Drugs Sales by Type (2024-2029) & (MT)
Table 50. US & Canada Neurodegenerative Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 51. US & Canada Neurodegenerative Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 52. US & Canada Neurodegenerative Drugs Sales by Application (2018-2024) & (MT)
Table 53. US & Canada Neurodegenerative Drugs Sales by Application (2024-2029) & (MT)
Table 54. US & Canada Neurodegenerative Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 55. US & Canada Neurodegenerative Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 56. US & Canada Neurodegenerative Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 57. US & Canada Neurodegenerative Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 58. US & Canada Neurodegenerative Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 59. US & Canada Neurodegenerative Drugs Sales by Country (2018-2024) & (MT)
Table 60. US & Canada Neurodegenerative Drugs Sales by Country (2024-2029) & (MT)
Table 61. Europe Neurodegenerative Drugs Sales by Type (2018-2024) & (MT)
Table 62. Europe Neurodegenerative Drugs Sales by Type (2024-2029) & (MT)
Table 63. Europe Neurodegenerative Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 64. Europe Neurodegenerative Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 65. Europe Neurodegenerative Drugs Sales by Application (2018-2024) & (MT)
Table 66. Europe Neurodegenerative Drugs Sales by Application (2024-2029) & (MT)
Table 67. Europe Neurodegenerative Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 68. Europe Neurodegenerative Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 69. Europe Neurodegenerative Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 70. Europe Neurodegenerative Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 71. Europe Neurodegenerative Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 72. Europe Neurodegenerative Drugs Sales by Country (2018-2024) & (MT)
Table 73. Europe Neurodegenerative Drugs Sales by Country (2024-2029) & (MT)
Table 74. China Neurodegenerative Drugs Sales by Type (2018-2024) & (MT)
Table 75. China Neurodegenerative Drugs Sales by Type (2024-2029) & (MT)
Table 76. China Neurodegenerative Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 77. China Neurodegenerative Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 78. China Neurodegenerative Drugs Sales by Application (2018-2024) & (MT)
Table 79. China Neurodegenerative Drugs Sales by Application (2024-2029) & (MT)
Table 80. China Neurodegenerative Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 81. China Neurodegenerative Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 82. Asia Neurodegenerative Drugs Sales by Type (2018-2024) & (MT)
Table 83. Asia Neurodegenerative Drugs Sales by Type (2024-2029) & (MT)
Table 84. Asia Neurodegenerative Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 85. Asia Neurodegenerative Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 86. Asia Neurodegenerative Drugs Sales by Application (2018-2024) & (MT)
Table 87. Asia Neurodegenerative Drugs Sales by Application (2024-2029) & (MT)
Table 88. Asia Neurodegenerative Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 89. Asia Neurodegenerative Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 90. Asia Neurodegenerative Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 91. Asia Neurodegenerative Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 92. Asia Neurodegenerative Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 93. Asia Neurodegenerative Drugs Sales by Region (2018-2024) & (MT)
Table 94. Asia Neurodegenerative Drugs Sales by Region (2024-2029) & (MT)
Table 95. Middle East, Africa and Latin America Neurodegenerative Drugs Sales by Type (2018-2024) & (MT)
Table 96. Middle East, Africa and Latin America Neurodegenerative Drugs Sales by Type (2024-2029) & (MT)
Table 97. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 98. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 99. Middle East, Africa and Latin America Neurodegenerative Drugs Sales by Application (2018-2024) & (MT)
Table 100. Middle East, Africa and Latin America Neurodegenerative Drugs Sales by Application (2024-2029) & (MT)
Table 101. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 102. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 103. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 104. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 106. Middle East, Africa and Latin America Neurodegenerative Drugs Sales by Country (2018-2024) & (MT)
Table 107. Middle East, Africa and Latin America Neurodegenerative Drugs Sales by Country (2024-2029) & (MT)
Table 108. Novartis Company Information
Table 109. Novartis Description and Major Businesses
Table 110. Novartis Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 111. Novartis Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Novartis Recent Developments
Table 113. Pfizer Company Information
Table 114. Pfizer Description and Major Businesses
Table 115. Pfizer Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 116. Pfizer Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Pfizer Recent Developments
Table 118. Merck Serono Company Information
Table 119. Merck Serono Description and Major Businesses
Table 120. Merck Serono Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 121. Merck Serono Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Merck Serono Recent Developments
Table 123. Biogen Idec Company Information
Table 124. Biogen Idec Description and Major Businesses
Table 125. Biogen Idec Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 126. Biogen Idec Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Biogen Idec Recent Developments
Table 128. TEVA Company Information
Table 129. TEVA Description and Major Businesses
Table 130. TEVA Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 131. TEVA Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. TEVA Recent Developments
Table 133. UCB Company Information
Table 134. UCB Description and Major Businesses
Table 135. UCB Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 136. UCB Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. UCB Recent Developments
Table 138. Boehringer Ingelheim Company Information
Table 139. Boehringer Ingelheim Description and Major Businesses
Table 140. Boehringer Ingelheim Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 141. Boehringer Ingelheim Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. Boehringer Ingelheim Recent Developments
Table 143. Sanofi Company Information
Table 144. Sanofi Description and Major Businesses
Table 145. Sanofi Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 146. Sanofi Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. Sanofi Recent Developments
Table 148. GlaxoSmithKline Company Information
Table 149. GlaxoSmithKline Description and Major Businesses
Table 150. GlaxoSmithKline Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 151. GlaxoSmithKline Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 152. GlaxoSmithKline Recent Developments
Table 153. Livzon Pharmaceutical Company Information
Table 154. Livzon Pharmaceutical Description and Major Businesses
Table 155. Livzon Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 156. Livzon Pharmaceutical Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 157. Livzon Pharmaceutical Recent Developments
Table 158. Haisco Pharmaceutical Company Information
Table 159. Haisco Pharmaceutical Description and Major Businesses
Table 160. Haisco Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 161. Haisco Pharmaceutical Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 162. Haisco Pharmaceutical Recent Developments
Table 163. Jingxin Pharmaceutical Company Information
Table 164. Jingxin Pharmaceutical Description and Major Businesses
Table 165. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 166. Jingxin Pharmaceutical Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 167. Jingxin Pharmaceutical Recent Developments
Table 168. Dongcheng Biochemicals Company Information
Table 169. Dongcheng Biochemicals Description and Major Businesses
Table 170. Dongcheng Biochemicals Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 171. Dongcheng Biochemicals Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 172. Dongcheng Biochemicals Recent Developments
Table 173. Hisun Pharmaceutical Company Information
Table 174. Hisun Pharmaceutical Description and Major Businesses
Table 175. Hisun Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 176. Hisun Pharmaceutical Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 177. Hisun Pharmaceutical Recent Developments
Table 178. Luye Pharma Company Information
Table 179. Luye Pharma Description and Major Businesses
Table 180. Luye Pharma Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 181. Luye Pharma Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 182. Luye Pharma Recent Developments
Table 183. Ark Pharmaceutical Company Information
Table 184. Ark Pharmaceutical Description and Major Businesses
Table 185. Ark Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 186. Ark Pharmaceutical Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 187. Ark Pharmaceutical Recent Developments
Table 188. Kanghong Pharmaceutical Company Information
Table 189. Kanghong Pharmaceutical Description and Major Businesses
Table 190. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 191. Kanghong Pharmaceutical Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 192. Kanghong Pharmaceutical Recent Developments
Table 193. Huahai Pharmaceutical Company Information
Table 194. Huahai Pharmaceutical Description and Major Businesses
Table 195. Huahai Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 196. Huahai Pharmaceutical Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 197. Huahai Pharmaceutical Recent Developments
Table 198. BORA PHARMACEUTICALS Company Information
Table 199. BORA PHARMACEUTICALS Description and Major Businesses
Table 200. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 201. BORA PHARMACEUTICALS Neurodegenerative Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 202. BORA PHARMACEUTICALS Recent Developments
Table 203. Key Raw Materials Lists
Table 204. Raw Materials Key Suppliers Lists
Table 205. Neurodegenerative Drugs Distributors List
Table 206. Neurodegenerative Drugs Customers List
Table 207. Neurodegenerative Drugs Market Trends
Table 208. Neurodegenerative Drugs Market Drivers
Table 209. Neurodegenerative Drugs Market Challenges
Table 210. Neurodegenerative Drugs Market Restraints
Table 211. Research Programs/Design for This Report
Table 212. Key Data Information from Secondary Sources
Table 213. Key Data Information from Primary Sources
List of Figures
Figure 1. Neurodegenerative Drugs Product Picture
Figure 2. Global Neurodegenerative Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Neurodegenerative Drugs Market Share by Type in 2022 & 2029
Figure 4. NMDA Product Picture
Figure 5. SSRIs Product Picture
Figure 6. Dopamine Inhibitors Product Picture
Figure 7. Global Neurodegenerative Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Neurodegenerative Drugs Market Share by Application in 2022 & 2029
Figure 9. Parkinson’s Disease
Figure 10. Huntington Disease
Figure 11. Amyotrophic Lateral Sclerosis
Figure 12. Alzheimer’s Disease
Figure 13. Neurodegenerative Drugs Report Years Considered
Figure 14. Global Neurodegenerative Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Neurodegenerative Drugs Revenue 2018-2029 (US$ Million)
Figure 16. Global Neurodegenerative Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 17. Global Neurodegenerative Drugs Revenue Market Share by Region (2018-2029)
Figure 18. Global Neurodegenerative Drugs Sales 2018-2029 ((MT)
Figure 19. Global Neurodegenerative Drugs Sales Market Share by Region (2018-2029)
Figure 20. US & Canada Neurodegenerative Drugs Sales YoY (2018-2029) & (MT)
Figure 21. US & Canada Neurodegenerative Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 22. Europe Neurodegenerative Drugs Sales YoY (2018-2029) & (MT)
Figure 23. Europe Neurodegenerative Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 24. China Neurodegenerative Drugs Sales YoY (2018-2029) & (MT)
Figure 25. China Neurodegenerative Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 26. Asia (excluding China) Neurodegenerative Drugs Sales YoY (2018-2029) & (MT)
Figure 27. Asia (excluding China) Neurodegenerative Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Neurodegenerative Drugs Sales YoY (2018-2029) & (MT)
Figure 29. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 30. The Neurodegenerative Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 31. The Top 5 and 10 Largest Manufacturers of Neurodegenerative Drugs in the World: Market Share by Neurodegenerative Drugs Revenue in 2022
Figure 32. Global Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Neurodegenerative Drugs Sales Market Share by Type (2018-2029)
Figure 34. Global Neurodegenerative Drugs Revenue Market Share by Type (2018-2029)
Figure 35. Global Neurodegenerative Drugs Sales Market Share by Application (2018-2029)
Figure 36. Global Neurodegenerative Drugs Revenue Market Share by Application (2018-2029)
Figure 37. US & Canada Neurodegenerative Drugs Sales Market Share by Type (2018-2029)
Figure 38. US & Canada Neurodegenerative Drugs Revenue Market Share by Type (2018-2029)
Figure 39. US & Canada Neurodegenerative Drugs Sales Market Share by Application (2018-2029)
Figure 40. US & Canada Neurodegenerative Drugs Revenue Market Share by Application (2018-2029)
Figure 41. US & Canada Neurodegenerative Drugs Revenue Share by Country (2018-2029)
Figure 42. US & Canada Neurodegenerative Drugs Sales Share by Country (2018-2029)
Figure 43. U.S. Neurodegenerative Drugs Revenue (2018-2029) & (US$ Million)
Figure 44. Canada Neurodegenerative Drugs Revenue (2018-2029) & (US$ Million)
Figure 45. Europe Neurodegenerative Drugs Sales Market Share by Type (2018-2029)
Figure 46. Europe Neurodegenerative Drugs Revenue Market Share by Type (2018-2029)
Figure 47. Europe Neurodegenerative Drugs Sales Market Share by Application (2018-2029)
Figure 48. Europe Neurodegenerative Drugs Revenue Market Share by Application (2018-2029)
Figure 49. Europe Neurodegenerative Drugs Revenue Share by Country (2018-2029)
Figure 50. Europe Neurodegenerative Drugs Sales Share by Country (2018-2029)
Figure 51. Germany Neurodegenerative Drugs Revenue (2018-2029) & (US$ Million)
Figure 52. France Neurodegenerative Drugs Revenue (2018-2029) & (US$ Million)
Figure 53. U.K. Neurodegenerative Drugs Revenue (2018-2029) & (US$ Million)
Figure 54. Italy Neurodegenerative Drugs Revenue (2018-2029) & (US$ Million)
Figure 55. Russia Neurodegenerative Drugs Revenue (2018-2029) & (US$ Million)
Figure 56. China Neurodegenerative Drugs Sales Market Share by Type (2018-2029)
Figure 57. China Neurodegenerative Drugs Revenue Market Share by Type (2018-2029)
Figure 58. China Neurodegenerative Drugs Sales Market Share by Application (2018-2029)
Figure 59. China Neurodegenerative Drugs Revenue Market Share by Application (2018-2029)
Figure 60. Asia Neurodegenerative Drugs Sales Market Share by Type (2018-2029)
Figure 61. Asia Neurodegenerative Drugs Revenue Market Share by Type (2018-2029)
Figure 62. Asia Neurodegenerative Drugs Sales Market Share by Application (2018-2029)
Figure 63. Asia Neurodegenerative Drugs Revenue Market Share by Application (2018-2029)
Figure 64. Asia Neurodegenerative Drugs Revenue Share by Region (2018-2029)
Figure 65. Asia Neurodegenerative Drugs Sales Share by Region (2018-2029)
Figure 66. Japan Neurodegenerative Drugs Revenue (2018-2029) & (US$ Million)
Figure 67. South Korea Neurodegenerative Drugs Revenue (2018-2029) & (US$ Million)
Figure 68. China Taiwan Neurodegenerative Drugs Revenue (2018-2029) & (US$ Million)
Figure 69. Southeast Asia Neurodegenerative Drugs Revenue (2018-2029) & (US$ Million)
Figure 70. India Neurodegenerative Drugs Revenue (2018-2029) & (US$ Million)
Figure 71. Middle East, Africa and Latin America Neurodegenerative Drugs Sales Market Share by Type (2018-2029)
Figure 72. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue Market Share by Type (2018-2029)
Figure 73. Middle East, Africa and Latin America Neurodegenerative Drugs Sales Market Share by Application (2018-2029)
Figure 74. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue Market Share by Application (2018-2029)
Figure 75. Middle East, Africa and Latin America Neurodegenerative Drugs Revenue Share by Country (2018-2029)
Figure 76. Middle East, Africa and Latin America Neurodegenerative Drugs Sales Share by Country (2018-2029)
Figure 77. Brazil Neurodegenerative Drugs Revenue (2018-2029) & (US$ Million)
Figure 78. Mexico Neurodegenerative Drugs Revenue (2018-2029) & (US$ Million)
Figure 79. Turkey Neurodegenerative Drugs Revenue (2018-2029) & (US$ Million)
Figure 80. Israel Neurodegenerative Drugs Revenue (2018-2029) & (US$ Million)
Figure 81. GCC Countries Neurodegenerative Drugs Revenue (2018-2029) & (US$ Million)
Figure 82. Neurodegenerative Drugs Value Chain
Figure 83. Neurodegenerative Drugs Production Process
Figure 84. Channels of Distribution
Figure 85. Distributors Profiles
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed